
Effects of the SGLT2 Inhibitor Dapagliflozin on Proteinuria in Non-diabetic patients with CKD (diamond): A Randomized Double-blind crossover trial
This paper was presented on October 23rd 2020 at the American Society of Nephrology’s Kidney Week 2020 Reimagined virtual conference by Dr Hiddo Heerspink from